Olsalazine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Olsalazine
Olsalazine.svg
Systematic (IUPAC) name
5-[(2Z)-2-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazino]-2-hydroxybenzoic acid
Clinical data
Trade names Dipentum
AHFS/Drugs.com monograph
MedlinePlus a601088
Pregnancy cat.
Legal status
Pharmacokinetic data
Protein binding 99%
Half-life 0.9 hours
Identifiers
CAS number 15722-48-2 YesY
ATC code A07EC03
PubChem CID 6003770
DrugBank DB01250
ChemSpider 10642377 YesY
UNII ULS5I8J03O YesY
KEGG D00727 N
ChEMBL CHEMBL571540 N
Chemical data
Formula C14H10N2O6 
Mol. mass 302.239g/mol
 N (what is this?)  (verify)

Olsalazine is an anti-inflammatory drug used in the treatment of inflammatory bowel disease such as ulcerative colitis. It is sold under the name Dipentum.

The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.

Like balsalazide, olsalazine is believed to deliver mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.

History[edit]

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply[edit]

The drug is supplied by UCB Pharma.

Other indications[edit]

The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine.

External links[edit]